Agenovir

Agenovir Corporation was a biotechnology company founded in 2014 to develop a novel class of human therapeutics targeting diseases caused by latent or persistent viral reservoirs. Built on CRISPR/Cas9 and other nuclease technology from the Stephen Quake lab at Stanford, it designed and simulated nucleases in silico at scale to disrupt intracellular viral DNA. It raised a $10.6M Series A led by DCVC (Data Collective) with Celgene and Lightspeed Venture Partners, and was acquired by Vir Biotechnology in 2018. It is a therapeutics company with no public developer, API, or SDK surface.

Agenovir is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Therapeutics, CRISPR, and Gene Editing.

🌐 Visit website 📡 Source on GitHub

5.7/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyBiotechnologyTherapeuticsCRISPRGene EditingAntiviralLife SciencesAcquired

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 5.7/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 0.0 / 20

Commercial Clarity 0.0 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/agenovir: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Source (apis.yml)

aid: agenovir
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/agenovir.png
name: Agenovir
description: Agenovir Corporation was a biotechnology company founded in 2014 to develop a novel class of human therapeutics
  targeting diseases caused by latent or persistent viral reservoirs. Built on CRISPR/Cas9 and other nuclease technology from
  the Stephen Quake lab at Stanford, it designed and simulated nucleases in silico at scale to disrupt intracellular viral
  DNA. It raised a $10.6M Series A led by DCVC (Data Collective) with Celgene and Lightspeed Venture Partners, and was acquired
  by Vir Biotechnology in 2018. It is a therapeutics company with no public developer, API, or SDK surface.
url: https://raw.githubusercontent.com/api-evangelist/agenovir/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- dcvc
x-tier: stub
x-tier-reason: portfolio-lead
x-status: acquired
x-acquired-by: Vir Biotechnology
x-acquired-year: 2018
x-api-surface: none
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-20'
tags:
- Company
- Biotechnology
- Therapeutics
- CRISPR
- Gene Editing
- Antiviral
- Life Sciences
- Acquired
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-20'
  status: minimal
  artifacts_added: 0
  pass: local-v1